• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定 105 种与 aHUS 相关的因子 H 变体的功能:对变异分类的启示。

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification.

机构信息

Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.

出版信息

Blood. 2021 Dec 2;138(22):2185-2201. doi: 10.1182/blood.2021012037.

DOI:10.1182/blood.2021012037
PMID:34189567
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8641096/
Abstract

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy that can progress, when untreated, to end-stage renal disease. Most frequently, aHUS is caused by complement dysregulation due to pathogenic variants in genes that encode complement components and regulators. Among these genes, the factor H (FH) gene, CFH, presents with the highest frequency (15% to 20%) of variants and is associated with the poorest prognosis. Correct classification of CFH variants as pathogenic or benign is essential to clinical care but remains challenging owing to the dearth of functional studies. As a result, significant numbers of variants are reported as variants of uncertain significance. To address this knowledge gap, we expressed and functionally characterized 105 aHUS-associated FH variants. All FH variants were categorized as pathogenic or benign and, for each, we fully documented the nature of the pathogenicity. Twenty-six previously characterized FH variants were used as controls to validate and confirm the robustness of the functional assays used. Of the remaining 79 uncharacterized variants, only 29 (36.7%) alter FH expression or function in vitro and, therefore, are proposed to be pathogenic. We show that rarity in control databases is not informative for variant classification, and we identify important limitations in applying prediction algorithms to FH variants. Based on structural and functional data, we suggest ways to circumvent these difficulties and, thereby, improve variant classification. Our work highlights the need for functional assays to interpret FH variants accurately if clinical care of patients with aHUS is to be individualized and optimized.

摘要

非典型溶血性尿毒症综合征 (aHUS) 是一种危及生命的血栓性微血管病,如果不治疗,可进展为终末期肾病。最常见的是,由于编码补体成分和调节剂的基因突变导致补体失调引起 aHUS。在这些基因中,因子 H (FH) 基因、CFH 出现变异的频率最高(15% 至 20%),且与预后最差相关。正确分类 CFH 变异是致病性的还是良性的对于临床护理至关重要,但由于缺乏功能研究,仍然具有挑战性。因此,大量的变异被报告为意义不明的变异。为了解决这一知识空白,我们表达并对 105 种与 aHUS 相关的 FH 变异进行了功能特征分析。所有 FH 变异均被归类为致病性或良性,并且为每种变异都充分记录了致病性的性质。26 种先前表征的 FH 变异用作对照,以验证和确认所使用的功能测定的稳健性。在剩余的 79 种未表征的变异中,只有 29 种(36.7%)在体外改变 FH 的表达或功能,因此被认为是致病性的。我们表明,在对照数据库中罕见并不能为变异分类提供信息,并且我们确定了将预测算法应用于 FH 变异的重要局限性。基于结构和功能数据,我们提出了克服这些困难的方法,从而改善了变异分类。我们的工作强调了需要进行功能测定来准确解释 FH 变异,如果要对 aHUS 患者进行个体化和优化的临床护理。

相似文献

1
Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification.鉴定 105 种与 aHUS 相关的因子 H 变体的功能:对变异分类的启示。
Blood. 2021 Dec 2;138(22):2185-2201. doi: 10.1182/blood.2021012037.
2
Complete functional characterization of disease-associated genetic variants in the complement factor H gene.全面功能分析补体因子 H 基因中与疾病相关的遗传变异。
Kidney Int. 2018 Feb;93(2):470-481. doi: 10.1016/j.kint.2017.07.015. Epub 2017 Sep 21.
3
Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.基因转换事件产生的因子 H 竞争物与非典型溶血尿毒综合征相关。
J Am Soc Nephrol. 2018 Jan;29(1):240-249. doi: 10.1681/ASN.2017050518. Epub 2017 Oct 9.
4
Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.补体因子H、FHR-3和FHR-1变异体在一个扩展单倍型中相关联,赋予非典型溶血尿毒综合征更高的风险。
Mol Immunol. 2015 Oct;67(2 Pt B):276-86. doi: 10.1016/j.molimm.2015.06.021. Epub 2015 Jul 7.
5
Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.补体攻击导致内皮细胞和血小板上唾液酸识别紊乱,引起非典型溶血尿毒综合征。
Blood. 2016 Jun 2;127(22):2701-10. doi: 10.1182/blood-2015-11-680009. Epub 2016 Mar 22.
6
Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.补体基因罕见功能变体与抗 FH 自身抗体相关的 aHUS。
Front Immunol. 2019 May 1;10:853. doi: 10.3389/fimmu.2019.00853. eCollection 2019.
7
Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.对 400 名患者进行基因分析,深化了对非典型溶血尿毒综合征的认识并提示了一个新基因的作用。
J Am Soc Nephrol. 2018 Dec;29(12):2809-2819. doi: 10.1681/ASN.2018070759. Epub 2018 Oct 30.
8
High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele .高补体因子 H 相关(FHR)-3 水平与非典型溶血尿毒综合征风险等位基因相关。
Front Immunol. 2018 Apr 24;9:848. doi: 10.3389/fimmu.2018.00848. eCollection 2018.
9
Complement Genetic Variants and FH Desialylation in -Haemolytic Uraemic Syndrome.补体遗传变异与 FH 去唾液酸化在溶血尿毒综合征中的作用。
Front Immunol. 2021 Mar 11;12:641656. doi: 10.3389/fimmu.2021.641656. eCollection 2021.
10
Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD.在 aHUS、C3G 和 AMD 中补体因子 H N 端稀有遗传变异的功能特征。
Front Immunol. 2021 Jan 14;11:602284. doi: 10.3389/fimmu.2020.602284. eCollection 2020.

引用本文的文献

1
Approach to the prevention of atypical hemolytic uremic syndrome recurrence using eculizumab in a pregnant kidney transplant recipient with complement factor H gene mutation: a case report and literature review.在一名患有补体因子H基因突变的妊娠肾移植受者中使用依库珠单抗预防非典型溶血性尿毒症综合征复发的方法:病例报告及文献综述
J Nephrol. 2025 Jul 11. doi: 10.1007/s40620-025-02342-1.
2
Atypical Hemolytic Uremic Syndrome/Complement-Mediated Thrombotic Microangiopathy Triggered by SARS-CoV-2 Infection: A Case Report.由新型冠状病毒肺炎感染引发的非典型溶血性尿毒症综合征/补体介导的血栓性微血管病:一例报告
Case Rep Nephrol Dial. 2025 Apr 28;15(1):119-124. doi: 10.1159/000545798. eCollection 2025 Jan-Dec.
3

本文引用的文献

1
Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases.FHR-1 与非典型溶血尿毒综合征及其他疾病关联的分子基础。
Blood. 2021 Jun 24;137(25):3484-3494. doi: 10.1182/blood.2020010069.
2
The mutational constraint spectrum quantified from variation in 141,456 humans.从 141456 名人类个体的变异中量化的突变约束谱。
Nature. 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May 27.
3
CADD: predicting the deleteriousness of variants throughout the human genome.CADD:预测整个人类基因组中变异的有害性。
The Art and Science of Genetic Counseling in Nephrology.
肾脏病学中遗传咨询的艺术与科学
Kidney360. 2025 Apr 23;6(7):1230-1244. doi: 10.34067/KID.0000000825.
4
Atypical Hemolytic Uremic Syndrome: A Review of Complement Dysregulation, Genetic Susceptibility and Multiorgan Involvement.非典型溶血性尿毒症综合征:补体失调、遗传易感性及多器官受累综述
J Clin Med. 2025 Apr 7;14(7):2527. doi: 10.3390/jcm14072527.
5
Development and Characterization of Novel ELISAs for the Specific Quantification of the Factor H-Related Proteins 2, 3, 4, and 5.用于特异性定量因子H相关蛋白2、3、4和5的新型酶联免疫吸附测定法的开发与特性分析
J Innate Immun. 2025;17(1):226-243. doi: 10.1159/000545139. Epub 2025 Mar 26.
6
Effective long-term treatment with moss-produced factor H by overcoming the antibody response in a mouse model of C3G.通过在C3G小鼠模型中克服抗体反应,用苔藓产生的因子H进行有效的长期治疗。
Front Immunol. 2025 Mar 7;16:1535547. doi: 10.3389/fimmu.2025.1535547. eCollection 2025.
7
Functional characterisation of missense ceruloplasmin variants and real-world prevalence assessment of Aceruloplasminemia using population data.运用群体数据对铜蓝蛋白错义变异体进行功能特性分析及对无铜蓝蛋白血症进行真实世界患病率评估。
EBioMedicine. 2025 Mar;113:105625. doi: 10.1016/j.ebiom.2025.105625. Epub 2025 Mar 4.
8
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.非典型溶血性尿毒症综合征:诊断、管理及治疗的终止
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):200-205. doi: 10.1182/hematology.2024000543.
9
Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy.补体生物传感器可识别补体介导的血栓性微血管病中的经典途径刺激物。
Blood. 2024 Dec 12;144(24):2528-2545. doi: 10.1182/blood.2024025850.
10
Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report.抗 C5 单克隆抗体治疗导致补体介导的非典型溶血尿毒综合征的病理缓解:一例报告。
BMC Nephrol. 2024 Jul 15;25(1):224. doi: 10.1186/s12882-024-03662-3.
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894. doi: 10.1093/nar/gky1016.
4
Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.儿童非典型溶血尿毒综合征的肾外表现。
Pediatr Nephrol. 2018 Aug;33(8):1395-1403. doi: 10.1007/s00467-018-3933-3. Epub 2018 Apr 2.
5
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.罕见补体变异的统计学验证为非典型溶血尿毒症综合征和 C3 肾小球病的分子基础提供了新见解。
J Immunol. 2018 Apr 1;200(7):2464-2478. doi: 10.4049/jimmunol.1701695. Epub 2018 Mar 2.
6
Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.基因转换事件产生的因子 H 竞争物与非典型溶血尿毒综合征相关。
J Am Soc Nephrol. 2018 Jan;29(1):240-249. doi: 10.1681/ASN.2017050518. Epub 2017 Oct 9.
7
Complete functional characterization of disease-associated genetic variants in the complement factor H gene.全面功能分析补体因子 H 基因中与疾病相关的遗传变异。
Kidney Int. 2018 Feb;93(2):470-481. doi: 10.1016/j.kint.2017.07.015. Epub 2017 Sep 21.
8
Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses.补体I因子对C3b的调节依赖性加工机制可实现免疫反应的分化。
Nat Struct Mol Biol. 2017 Aug;24(8):643-651. doi: 10.1038/nsmb.3427. Epub 2017 Jul 3.
9
The lectin self of complement factor H.补体因子 H 的凝集素自身。
Curr Opin Struct Biol. 2017 Jun;44:111-118. doi: 10.1016/j.sbi.2017.01.005. Epub 2017 Feb 9.
10
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.癌症序列变异解读与报告的标准和指南:分子病理学协会、美国临床肿瘤学会和美国病理学家学会联合共识推荐
J Mol Diagn. 2017 Jan;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002.